Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 7/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.36 |
| ▸ | TAS1R2 | Q8TE23 | 3/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.34 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29438324 | 1.00 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL20621846 | 1.00 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL29965797 | 1.00 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL29965116 | 0.90 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL29438263 | 0.90 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL21875792 | 0.90 | P2RX7 (0.37) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL21875777 | 0.88 | P2RX7 (0.38) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL29964247 | 0.88 | P2RX7 (0.38) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL21875837 | 0.86 | P2RX7 (0.39) | P2RX7BRD4CREBBPTAS1R3TAS1R1 | |
| SCHEMBL29438305 | 0.86 | P2RX7 (0.39) | P2RX7BRD4CREBBPTAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3897843-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2021-10-27 | — | — | EP | claimed |
| CN-113474044-A | Bicyclic derivatives | 瑞士伊兰科动物保健有限公司 | 2021-10-01 | — | — | CN | claimed |
| WO-2020131629-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-3615527-B1 | NEW AZAQUINOLINE DERIVATIVES | ELANCO ANIMAL HEALTH GMBH (DE) | 2024-03-06 | — | — | EP | disclosed |
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| US-11485733-B2 | Azaquinoline derivatives | BAYER ANIMAL HEALTH GMBH (DE) | 2022-11-01 | — | — | US | disclosed |
| EP-3897843-A1 | BICYCLIC DERIVATIVES | Elanco Tiergesundheit AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113474044-A | Bicyclic derivatives | 瑞士伊兰科动物保健有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020131629-A1 | BICYCLIC DERIVATIVES | ELANCO TIERGESUNDHEIT AG (CH) | 2020-06-25 | — | — | WO | disclosed |
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | BAYER ANIMAL HEALTH GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200131175-A1 | NEW AZAQUINOLINE DERIVATIVES | RECQL, H1-5, CHRM1 | P2RX7 97/4885BRD4 935/4885CREBBP 4608/4885 |
| US-11485733-B2 | Azaquinoline derivatives | RECQL, H1-5, H1-3 | P2RX7 72/4885BRD4 1125/4885CREBBP 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.